(E)-1-isopropyl-4-(4-methoxystyryl)benzene | 24787-27-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-1-isopropyl-4-(4-methoxystyryl)benzene
• 英文别名: (4'-isopropyl-stilben-4-yl)-methyl ether；(4'-Isopropyl-stilben-4-yl)-methyl-aether；4'-Methoxy-4-isopropyl-stilben；trans-4-Isopropyl-4'-methoxy-stilben；1-methoxy-4-[(E)-2-(4-propan-2-ylphenyl)ethenyl]benzene
• CAS: 24787-27-7
• 化学式: C₁₈H₂₀O
• 分子量: 252.356
• InChiKey: VUBWASQPOCZJDV-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-(4-isopropyl-phenyl)-3-(4-methoxy-phenyl)-acrylic acid 生成 (E)-1-isopropyl-4-(4-methoxystyryl)benzene
  参考文献：
  名称：

  Magnanini, Gazzetta Chimica Italiana, 1885, vol. 15, p. 513

  摘要：

  DOI：

文献信息

• Anil-Synthese. 3. Mitteilung [1] Über die Darstellung von Styryl-Derivaten aus methyl-substituierten carbocyclischen Aromaten
  作者：A. E. Siegrist、P. Liechti、H. R. Meyer、K. Weber

  DOI：10.1002/hlca.19690520836

  日期：——

  1,4-Diphenylbutadien-, Tolan-, 1,4-Diphenylbutadiin-, Naphtalin-, Anthracen-und Phenanthren-Reihe werden mit Anilen aromatischer Aldehyde in Dimethylformamid in Gegenwart von Kaliumhydroxid oder Kalium-t-butylat zu Styryl-Derivaten umgesetzt.

  甲基取代碳环芳烃，二苯基，三联苯，Stilben-，1,4-二苯基丁二烯-，Tolan-，1,4-二苯基丁二烯-，萘酚-，蒽环与苯并蒽-苯并二氮杂-苯并二氢萘Gegenwart von Kaliumhydroxid oder Kal-叔丁基中的二甲基甲酰胺。
• Analogs of fexaramine and methods of making and using
  申请人：Salk Institute for Biological Studies

  公开号：US10301268B2

  公开（公告）日：2019-05-28

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

  具有以下式子的新型化合物 本文公开了具有式的新型化合物、其制造方法的实施方案以及包含它们的组合物。还公开了一种治疗或预防受试者代谢紊乱的方法的实施方案，包括向受试者施用（例如通过胃肠道）治疗有效量的一种或多种已公开化合物，从而激活肠道中的FXR受体，治疗或预防受试者的代谢紊乱。此外，还公开了一种治疗或预防受试者肠道区域炎症的方法的实施方案，该方法包括向受试者施用（例如，经由胃肠道）治疗有效量的一种或多种所公开化合物，从而激活肠道中的FXR受体，进而治疗或预防受试者肠道区域的炎症。
• H₂SO₄-Promoted Synthesis of (<i>E</i>)-Stilbenes from Substituted Phenylacetones and Substituted Benzaldehydes Through Tandem Aldol–Grob Reaction
  作者：T. Narender、K. Papi Reddy、Sriniwas Tiwari

  DOI：10.1080/00397911.2010.488309

  日期：2011.5.3

  [image omitted] Stilbene derivates (stilbenoids) are present in plants and show a wide range of biological activities and potential therapeutic value. In continuation of our natural product synthesis program, an efficient, simple, and practical method has been developed to regioselectively synthesize (E)-stilbenes using H2SO4 as a catalyst in a short time (30-60s) at room temperature in good to excellent yields.
• Magnanimi, Gazzetta Chimica Italiana, 1885, vol. 15, p. 509
  作者：Magnanimi

  DOI：——

  日期：——
• ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING
  申请人：Salk Institute for Biological Studies

  公开号：US20170066724A1

  公开（公告）日：2017-03-09

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.